Drug lookup | Fillwise

TRYPTOPHAN

All products: not a benefit

Apo-Tryptophan · DIN 02248538 · 500mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Tryptophan · DIN 02248538 Manufacturer: Apotex Inc.; listing date 2008-06-27 Health Canada: Marketed since 2003-12-09 · brand APO-TRYPTOPHAN · ATC N06AX02 TRYPTOPHAN · form Tablet · route Oral · ingredients TRYPTOPHAN 500 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72892 · Verify on the e-Formulary ↗ (DIN 02248538)

Source record

DIN 02248538: Apo-Tryptophan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281612029; group id 513; item number 1358; lccId None; manufacturer id APX Source form: Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.8295; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248538 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72892

Interchangeable products

Ratio-Tryptophan · DIN 02240333 · not recorded Tryptan · DIN 02029456 · not recorded

Shortage status: shortage reported ended 2026-06-25 (report last updated 2026-06-25); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248538

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (28:16:12 Other Psychotropics) and how they are covered

Matched class: 28:16:12 Other Psychotropics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): LITHIUM CARBONATE 28:16:12 Other Psychotropics

LITHIUM CARBONATE

· 12 products · General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 150mg, 300mg · Cap, ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:12

Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS TRYPTAN is indicated: as a valuable adjunct to antidepressant drug treatment in the management of patients suffering from depressive disorders (bipolar affective disorders). https://pdf.hres.ca/dpd_pm/00061741.PDF PM date: June 9, 2021 Source product: TRYPTAN; DIN 00654531; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Tryptophan · DIN 02248538 Shortage status: shortage reported ended 2026-06-25 (report last updated 2026-06-25); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248538

Check this DIN again

Other review policies

For Apo-Tryptophan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026